title: Acute coronary syndrome: short-term effects of early intravenous metoprolol on maximum P wave duration and P wave dispersion.
abstract: In patients with acute coronary syndrome (ACS), the presence of atrial fibrillation (AF) results in worse inpatient outcomes than in those without AF. Two electrocardiographic markers, maximum P wave duration (P(maximum)) and P wave dispersion (P(dispersion)), have been assessed because they reflect conduction abnormalities in patients with paroxysmal AF. b blockers are known to have beneficial effects in patients with ACS. This prospective study was conducted to investigate whether early intravenous (IV) metoprolol injection acutely decreases P(maximum) and P(dispersion) in patients with ACS. This study involved 100 consecutive patients with ACS who were divided into 2 groups according to whether or not they received early IV metoprolol. Group 1 consisted of 19 patients who received IV metoprolol within 3 h after onset of symptoms, and group 2 consisted of 81 patients who did not receive IV metoprolol within 3 h after symptom onset because of late admission. P(maximum) and P(dispersion) were measured on admission and again at 2 h after admission. Two-dimensional echocardiographic examination was also performed. For patients who received early IV metoprolol, P(maximum) and P(dispersion), measured 2 h after admission, were shorter than values at admission (P<.001). Conversely, P(maximum) and P(dispersion), measured 2 h after admission, did not differ significantly from values at admission in patients who did not receive early IV metoprolol (P=.292 and P=.236, respectively). IV administration of metoprolol reduced values for P(maximum) and P(dispersion), measured 2 h after admission, among patients with ACS who were admitted within 3 h after onset of symptoms.
authors.affiliation: Department of Cardiology, Cumhuriyet University, Sivas, Turkey. okanturgut@walla.com
authors.forename: Okan
authors.initials: O
authors.lastname: Turgut
authors.forename: M Birhan
authors.initials: MB
authors.lastname: Yilmaz
authors.forename: Ahmet
authors.initials: A
authors.lastname: Yilmaz
authors.forename: Kenan
authors.initials: K
authors.lastname: Yalta
authors.forename: Omer
authors.initials: O
authors.lastname: Kendirlioglu
authors.forename: Izzet
authors.initials: I
authors.lastname: Tandogan
mesh_terms: D000208:Acute Disease; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000517:prevention & control*; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy*; D004452:Echocardiography; D004562:Electrocardiography; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008790:Metoprolol / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D008790:Metoprolol